Rockefeller Capital Management’s Aquestive Therapeutics AQST Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$69.4K Sell
15,000
-1,604
-10% -$7.13K ﹤0.01% 3277
2026
Q2
$69.1K Sell
16,604
-2,200
-12% -$9.26K ﹤0.01% 3189
2026
Q1
$78K Buy
18,804
+1,608
+9% +$6.53K ﹤0.01% 3015
2025
Q4
$111K Sell
17,196
-18,309
-52% -$114K ﹤0.01% 2670
2025
Q3
$198K Buy
+35,505
New +$154K ﹤0.01% 2236
2023
Q1
– Sell
-3,166
Closed -$2K – 2080
2022
Q4
$2K Hold
3,166
– – ﹤0.01% 3539
2022
Q3
$3K Hold
3,166
– – ﹤0.01% 3459
2022
Q2
$2K Hold
3,166
– – ﹤0.01% 3746
2022
Q1
$8K Hold
3,166
– – ﹤0.01% 3142
2021
Q4
$12K Hold
3,166
– – ﹤0.01% 2872
2021
Q3
$13K Hold
3,166
– – ﹤0.01% 2755
2021
Q2
$12K Hold
3,166
– – ﹤0.01% 2693
2021
Q1
$16K Buy
3,166
+964
+44% +$5.13K ﹤0.01% 2369
2020
Q4
$11K Sell
2,202
-1,818
-45% -$10.9K ﹤0.01% 2195
2020
Q3
$19K Buy
+4,020
New +$26.3K ﹤0.01% 1799

Other funds holding AQST

Rockefeller Capital Management's AQST Position: Q3 2026 in Review

Rockefeller Capital Management reduced its Aquestive Therapeutics (AQST) stake by 9.7% in Q3 2026, selling an estimated $7.13K and leaving 15,000 shares worth $69.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3277.

Rockefeller Capital Management first reported a position in AQST in Q3 2020 and has held it in 15 quarters since. The position peaked at $198K in Q3 2025. 190 funds tracked by Wall St. Rank hold AQST as of Q3 2026.

  • Rockefeller Capital Management held 15,000 shares of Aquestive Therapeutics worth $69.4K as of Q3 2026.
  • Rockefeller Capital Management sold 1,604 Aquestive Therapeutics shares in Q3 2026, an estimated $7.13K.
  • Aquestive Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q3 2026, its #3277 holding.
  • Rockefeller Capital Management first reported a position in Aquestive Therapeutics in Q3 2020 and has held it in 15 quarters since.
  • Rockefeller Capital Management's Aquestive Therapeutics position peaked at $198K in Q3 2025.
  • 190 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q3 2026.

Based on Rockefeller Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.